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1270periprocedural intracardiac echocardiography with
transesophageal echocardiography performed 6
months after transseptal puncture. We agree with
Ren et al. that it is not clear whether iASD persistence
accounts for adverse outcomes after MitraClip pro-
cedures or whether the persistence of an ASD just
reﬂects adverse conditions, which lead to higher
mortality and impaired functional outcomes.
The cited “discrepancies” between left ventric-
ular end-diastolic and end-systolic volumes in pa-
tients with or without iASD were not statistically
signiﬁcant, and therefore, it is highly hypothetical
to draw any conclusion from this ﬁnding, which
might be due to play of chance in a small patient
cohort. LVEF, derived from left ventricular end-
diastolic and end-systolic volumes, was entered
into regression analysis and failed to show signif-
icance for the prediction of 6-month mortality
rates.
Most of all, the aim of our study was to assess the
persistence rate of iASDs after MitraClip procedure
and to report a possible inﬂuence on functional
outcome. We did not aim to measure development of
ASD sizes and echocardiographic ﬂow features. We
doubt the reliability of 2-dimensional echocardio-
graphy for sizing small iASDs occurring in mobile
anatomical structures and echocardiography can only
give us a rough estimate of the true ASD sizes.
The hemodynamic consequences of ASDs should be
determined with invasive measures as depicted by
current guidelines (3,4).
We feel that our work contributes to a more careful
evaluation of patients with persistent iASD after
transseptal procedures, which might help lead to a
better understanding and, in addition, to increased
watchfulness regarding the clinical consequences of
interatrial shunting in such patients.Robert Schueler, MD
*Christoph Hammerstingl, MD
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Defect After MitraClip
TherapyAfter reading the recent paper in JACC: Cardiovascu-
lar Interventions by Schueler et al. (1) describing the
persistence of iatrogenic atrial septal defects (iASDs)
after MitraClip therapy, we wish to point out an
important omission. The authors stated that “persis-
tence rates of iASDs after MitraClip procedures [are]
unknown,” and “this is the ﬁrst study investigating
the persistence rates of iASD after interventional
edge-to-edge repair.” In fact, our group published the
ﬁrst investigation on this topic in 2012, and we were
surprised to see that our paper was not referenced in
the paper or accompanying editorial (2). We reported
on the incidence of iASD in 30 subjects undergoing
MitraClip repair during the roll-in phase of the
EVEREST II (Pivotal Study of a Percutaneous Mitral
Valve Repair System) randomized trial, who had
interpretable baseline, 30-day, and 6- and 12-month
transthoracic echocardiograms (TTE). We found that
iASDs were detectable in 27% of patients at 12 months
by TTE. Although this is lower than the 50% preva-
lence of iASD detected at 6 months by Schueler et al.
(1), their group used transesophageal echocardiogra-
phy, which is more sensitive for iASD detection.
Similar to Schueler et al. (1), we found that there was
less regression in left ventricular size in patients with
iASD. Importantly, we found that subjects with iASD
at 12 months had more residual mitral regurgitation
(MR), increased tricuspid regurgitation, and a trend
toward larger LA volumes than non-iASD patients.
Eighty-three percent of non-ASD patients were free
from MR >2þ at 12 months versus 38% of those with
iASD (p ¼ 0.016). We did not note any adverse clinical
events related to the presence of iASD. It is probably
fair to say that the true signiﬁcance of iASD remains
unknown and may be related to other procedural or
patient-level factors not well understood. Consider-
ation for transcatheter closure of iASD should be
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1271evaluated on a case-by-case basis and could be
considered in patients with left-to-right shunt and
evidence of progressive right ventricular or atrial
enlargement, right-sided chamber dysfunction, or
worsening pulmonary hypertension. Closure of iASD
in patients with persistent right-to-left shunt with
paradoxical embolus or arterial desaturation (hypox-
emia) might also be reasonable.*Jason H. Rogers, MD
Thomas Smith, MD
*Division of Cardiovascular Medicine
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Drs. Rogers and Smith state that they were able to
publish data from the roll-in phase of the EVEREST
II (A Study of the Evalve Cardiovascular Valve Repair
[MitraClip] System Endovascular Valve Edge-to-Edge
Repair Study EVEREST II High Risk Registry) in 2012
reporting on markedly lower incidence rates of iat-
rogenic septal defect (iASD) after MitraClip use (27%)
(2). This group reported a correlation of detectable
iASD with cardiac remodeling (2), which was in part
conﬁrmed by our ﬁndings (1). Consequently, Drs.
Rogers and Smith question the novelty of our data.
Before we started our study program, we read their
paper with great interest and acknowledge this early
work. We want to point out that we did not deem
ourselves to be the ﬁrst group investigating inci-
dence rates of iASD after percutaneous mitral valve
repair. To the best of our knowledge we performed
the ﬁrst study in this ﬁeld “with serial TEE exami-
nations” (1).
Furthermore, several important differences be-
tween the 2 studies must be stressed, which makes a
head-to-head comparison impossible.First, Smith et al. (2) reported transthoracic echo-
cardiographic ﬁndings, which has important limita-
tions in this setting. Current guidelines deﬁne TEE
the gold standard for the evaluation of interatrial
shunt defects (3), and several studies were able to
show signiﬁcant differences in detectable iASD rates
if determined with transthoracic echocardiographic
ﬁndings or transesophageal echocardiography (TEE)
(4). Second, the main focus of our research was to
evaluate the correlation of iASD persistence with the
treated patients’ clinical outcomes, which was not
addressed by Smith et al. (2).
Third, we included nonsurgical, highest-risk pa-
tients, including 73% of subjects with functional
mitral valve regurgitation, which is in contrast to
Smith et al. (2) reporting on degenerative valve
disease in patients suitable for MV replacement.
The persistence rate of iASD and its clinical con-
sequences might differ relevantly between high-risk
heart failure patients and the early EVEREST II
population (5). As we discussed in our paper (1),
we agree with Smith and Rogers that the “true”
signiﬁcance of iASD after percutaneous mitral valve
repair remains unknown. Our results— in context
with available data—showed a noticeable correla-
tion of iASD persistence with patients’ functional
outcomes and survival. As we clearly stated (1), the
underlying pathomechanisms for iASD persistence
are not fully understood, and we emphasize the
need for prospective trials addressing this topic.
Currently, interventional closure of an iASD after
percutaneous mitral valve repair must be planned
based on a careful, individual case-by-case
decision.Robert Schueler, MD
*Christoph Hammerstingl, MD
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